are developed, manufactured & commercialized. |
 GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program. more Xcellerex Signs Memorandum of Understanding with SK Chemicals to Commercialize SK-Developed Vaccines with FlexFactory® Platform. more Xcellerex Announces Appointment of Guy Broadbent as President and Chief Executive Officer. more Xcellerex announces groundbreaking for new FlexFactory facility. more Xcellerex and partners announce completion of successful test of Rapid Production of Swine Flu H1 Hemagglutinin. more Humacyte and Xcellerex Announce Collaboration to Develop Single-use Manufacturing Technology for Growth of Vascular Grafts for Transplantation. more Xcellerex Initiates Phase I Clinical Trial of Novel Yellow Fever Vaccine. more Novavax and Xcellerex announce collaboration to develop large-scale manufacturing process for 2009 H1N1 Influenza VLP Vaccine.more Itero Biopharmaceuticals selects Xcellerex to enable cost effective production of specialty biopharmaceutical protein products more Xcellerex announces milestone sale of FlexFactory® biomanufacturing line and XDR single-use bioreactors to Crucell, N.V. more 
|
 |